Urology Times staff

“When we are starting to do this in urology across the world, we need to make sure that we have patient representatives involved and they are there from the beginning to make sure that whatever we do in terms of an intervention is successful,” says Nikita R. Bhatt, MBBS, MCh, MMed, FRCS.

Joshi Alumkal, MD, discusses the phase 3 TALAPRO-2 trial, which supported the FDA approval of the combination of talazoparib and enzalutamide for patients with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination repair gene defects.

“So far, all the studies have shown quite positive results with this approach. It's something that we can use in urology [for a lot of different issues],” says Nikita R. Bhatt, MBBS, MCh, MMed, FRCS.

In the setting of refractory urothelial carcinoma, Jue Wang, MD, says it is essential to thoroughly understand a patient's molecular profile, comorbidities, and residual side effects from prior lines of therapy.

“The recommendations are based on the current evidence, but the evidence is overall relatively weak. So, I think there's a lot of room for improvement,” says Neal E. Rowe, MD, FRCSC.

"When a patient or an imaging study identifies an incidental adrenal mass, the first upfront radiographic test is a non-contrast CT scan," says Neal E. Rowe, MD, FRCSC.

"We as a center prioritized using cisplatin and carboplatin for patients who are receiving curative intent chemotherapy," says Tian Zhang, MD.

The phase 3 THOR trial is the supporting trial for a supplemental New Drug Application for erdafitinib in urothelial carcinoma.

“At its core, [the book is] a love letter to my patients. It's all the things that I didn't have time to tell them in a 15-minute office visit,” says Martha Boone, MD.

"You have to take care of those basic needs, because if not, you're not going to have the space to react differently when you're getting triggered," says Diana Londoño, MD.

“We're going to be able to treat many more patients who suffer from BPH/LUTS with these less invasive options,” says Dean S. Elterman, MD, MSc, FRCSC.

"The purpose of the study is to compare the safety and efficacy of lutetium PSMA I&T vs standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer," says Jason M. Hafron, MD.

"Mentorship plays a huge role, and as someone who's interested in academics in the future, I think it's important to remember the influence that you can have on shaping young minds," says Niki Parikh, MD, MBA, MSBA.

“The world of surgery makes a person quite disciplined,” says Martha Boone, MD.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

"I would say the take-home message from this study is that HoLEP uptake has nearly doubled from 2016 to 2019," says Jenny Guo, MD.

“It's a really exciting time for people who are interested in BPH/LUTS,” says Dean S. Elterman, MD, MSc, FRCSC.

"I'm very pleased that this is now in the armamentarium for us," says Wayne G. Brisbane, MD.

"Interestingly enough, we found that PVP accounted for nearly a third of BPH surgeries back in 2016. This number drastically decreased to just 0.7% of all BPH surgeries in 2019," says Jenny Guo, MD.

"Only 25% of our respondents felt that sexual health curriculum provided an adequate fund of knowledge to address any of the sexual health concerns of patients," says Niki Parikh, MD, MBA, MSBA.

"If you've got a difference, pay attention to the size and direction. If you have a massive difference between groups in terms of outcome, but only a small difference in terms of baseline characteristics, that's worth talking about," says Andrew J. Vickers, PhD.

“Our identity is not just about a title; it's not just about that role. We are much bigger than that,” says Diana Londoño, MD.

"We had the idea of doing a scoping review of office-based BPH stents, as this is becoming a new and evolving hot topic in the area of male functional urology," Dean S. Elterman, MD, MSc, FRCSC.

"I've always written to just process emotions," says Martha Boone, MD.

“In terms of trying to help patients access the services, the biggest part is just being aware of what's available where you work,” says Sarah P. Psutka, MD, MS.

“I think it's extremely exciting to be part of something that is possibly practice changing, potentially field changing,” says Sandip M. Prasad, MD, MPhil.

“It's really important to pay attention to what's off balance,” says Diana Londoño, MD.

"We're interested in cause; that's why we often are doing observational research. Authors never face that head on, and don't really come to grips with it," says Andrew J. Vickers, PhD.

“I can tell you from a patient standpoint, I think we all agreed across the panel, there's going to be tremendous enthusiasm from patients about a nonsurgical option,” says Sandip M. Prasad, MD, MPhil.